Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- CSL’s Hemophilia Gene Therapy to Get Orphan Tag in Japan
February 6, 2024
- Truvada Clears Preliminary Review for PrEP Use, but Coverage Not Granted
February 6, 2024
- Generic Firms Required to Disclose Supply Info from June after Pilot Rollout of Company Indicators
February 5, 2024
- Will Truvada Win Health Coverage as Japan’s First Drug for HIV Prevention?
February 5, 2024
- MHLW to Kick Off Debates on PMD Act Amendment on Feb. 9
February 5, 2024
- Physician Meals Costs, Seminar Expenses Newly Subject to Disclosure under Clinical Trials Act from April
February 2, 2024
- Annual Drug Price Revisions Based on 4-Minister Agreement: Japan PM
February 2, 2024
- Japan to Introduce Fee Premium for Inpatient Biosimilar Use, Covering 13 APIs
February 1, 2024
- Drug Pricing, LLP Rule in MHLW’s Draft Supplementary Opinions for FY2024 Reform
February 1, 2024
- Japan to Revise Ad Guidelines to Address GLP-1 Use for Cosmetic Weight Loss
January 31, 2024
- MHLW to Require Pharma to Disclose More Categories of Physician Payments under Clinical Trials Act
January 30, 2024
- MEXT’s Draft Reform Guidelines Urge University Hospitals to Reduce Drug Costs
January 29, 2024
- Chuikyo to Discuss Exclusion of Long-Listed Biologics from New Coverage Scheme
January 29, 2024
- Japan’s Diet Kicks Off 150-Day Regular Session, MHLW Plans 4 Bills
January 29, 2024
- Jardiance’s CKD Indication in Line for Japan Approval with Key Panel Nod
January 29, 2024
- Break-Up of LDP Factions Won’t Have Major Impact on Pharma Policy, but Could Make Lobbying Tougher
January 26, 2024
- MHLW Holds 1st Meeting to Consider Structure of Japan CDC
January 26, 2024
- MHLW No Longer Requires Japanese Comparability Data for Certain Biosimilars: Q&A Update
January 26, 2024
- Cases of Xocova Use in Pregnant Women Now Total 34: MHLW
January 24, 2024
- As Japan Sees Uptick in COVID Cases, Minister Says to Watch Situations
January 24, 2024
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…